Age-dependent alteration of the renin-angiotensin-system (RAS) and generation of angiotensin II 23 (Ang II) are well documented. By contrast, RAS-independent generation of angiotensin II in 24 aging and its responses to exercise have not been explored. To this end, we examined the effects 25 of chymase, a secretory serine protease, on the angiotensin converting enzyme (ACE)-26 independent conversion of Ang I to Ang II. We hypothesize that age-dependent alteration of 27 cardiac Ang II formation is chymase-dependent in nature and is prevented by exercise training. 28
Introduction
were measured by ELISA (Mybiosource INC, San Diego, CA). Based on the instructions 131 provided by the manufacturer, pulverized whole hearts were homogenized in a sample buffer, 132 centrifuged at 1,000 xg for 10 minutes and the supernatant fractions were collected. In a 96-well 133 plate, 50 μl of samples or peptide standard solution was added to each well, followed by the 134 addition of 100 μl of horseradish peroxidase (HRP)-conjugate reagent. The plate was gently 135 mixed, covered with a plastic membrane, and incubated at 37 Enzymatic Activity: Nox activity was measured using an established lucigenin detection analysis 145 (28). Liquid N 2 pulverized hearts were homogenized in phosphate buffer containing 20mM 146 monophasic potassium phosphate KPO 4 , 1 mM EDTA and protease inhibitor cocktail. Samples 147 were centrifuged at 1000 g, the supernatant was aspirated and protein content was determined 148 using the Bradford method (Bio-Rad, Hercules, CA). The reaction was conducted in a final 149 volume of 1 mL, which contained reaction assay buffer (50 mM KPO 4 , 150 mM sucrose, and 1 150 mM EDTA pH 7.0), 5 μM lucigenin, and 100 μM NADPH. The reaction was initiated by the 151 addition of 50μl of homogenate (approximately 200 μg protein) that was pre-incubated with or 152 without 100 μM apocynin (inhibitor for Nox). The chemiluminescence generated by the reaction 153 was recorded for two minutes by scintillation counter (LS6000IC, Beckman Instruments). Nox 154 activity was calculated by subtracting the value of apocynin-treated fraction from total values 155 (without apocynin), and reported as CPM (counts/min)/μg protein after background subtraction. 156
Activities of ACE and ACE2 were determined using specific fluorometric substrates 157
Abz-FRK(Dnp)-P and Mca-APK(Dnp) (Enzo Life sciences, Farmingdale, NY) respectively 158 (19). Hearts were homogenized in 0.1 M Tris-HCl buffer containing 50 mM NaCl (pH 7.0) for 159 ACE and 0.2 M Tris-HCl containing 200 mM NaCl (pH 7.5) for ACE2. Samples were 160 centrifuged at 1000g for 10 min and the supernatant fraction was collected for analysis. Activity 161 assays were conducted in the same buffers with additional 10 μM ZnCl 2 . 10 μM of the 162 mol/l; specific inhibitor of ACE) in order to validate the specificity of the enzyme. 216
As shown in Figure 2c , cardiac ACE activity in the three groups of rats was eliminated by 217 captopril, confirming the specificity of the response. 218 ACE2 expression and activity are summarized in Figure 3 . As shown in panel (a), the 219 age-associated downregulation of cardiac ACE2 was not only normalized, but upregulated by 220 exercise training. In similar fashion, the pattern of decreased ACE2 activity was completely 221 reversed by exercise training to levels observed in control animals ( Figure 3b The local RAS in cardiomyocytes and coronary vessels is propelled by the de novo 284 synthesis of Ang I from renin, followed by conversion of Ang I to Ang II through the rate-285 limiting cleavage step by ACE (40; 44). Alternatively, an endopeptidase, chymase, has been 286 identified in human and animal hearts and constitutes a non ACE-related pathway for Ang II 287 production (21; 56). In this regard, chymase is believed to play a pivotal role in Ang II 288 formation in human hearts (55). The contribution of chymase to pathophysiological changes in 289 the cardiovascular system has attracted considerable attention, based on observations that long-290 term treatment of patients with ACE inhibitors is associated with a phenomenon known as 291 "angiotensin II escape", which is characterized as the rebound of circulating Ang II to 292 pretreatment levels (36). Additionally, evidence exists that show not all cardiac Ang II formation 293 and action are sensitive to angiotensin receptor blockers (ARBs) or ACE inhibitors (6; 15; 23). 294
Moreover, during the process of angiotensin signaling, local modifications/alterations in the 295 synthesis of Ang II can result from changes in activity and structure of RAS enzymes; such 296 changes can exacerbate with age-related excess of local Ang II (30). Reports show that cardiac-297 derived Ang II mediates cardiomyocyte remodeling. This remodeling is responsible for age-298 dependent cardiac dysfunction and heart failure observed in transgenic mice that develop Ang II-299 mediated cardiac hypertrophy in the absence of hypertension (17). In this context, the nature of 300 tissue-specific formation of Ang II as a function of aging formed the basis of the present study, 301 which was aimed to extend our current understanding of age-dependent changes in cardiac RAS 302 components and alternative formation of Ang II. Indeed, our results indicate that aged hearts 303 exhibit a significantly high level of Ang II (Figure 1b) , a finding that is paradoxically coupled to 304 declines in its precursor (Ang I; Figure 1a ) and its rate-limiting enzyme (ACE; Figure 2 ). This 305 negates the possibility that the response is ACE-dependent and challenges a generally acceptedconcept that the increased level of Ang II is due exclusively, to elevated ACE activity. As such,thus supporting chymase as the primary source for cardiac Ang II in aged rats. 310
Since mast cells are the predominant producers of chymase in heart tissue, the result of 311 increases in cardiac mast cells, as indicated by upregulation of tryptase (Figure 4c One study has also demonstrated a switch from ACE-dependent to ACE-independent 325 formation of Ang II during progression of metabolic syndrome, an age-dependent metabolic 326 disorder. Accordingly, diabetic kidneys exhibit vasoconstriction in response to exogenous 327 administration of Ang I. This response was sensitive to inhibitors of serine protease (chymase) 328 but resistant to those of ACE. An effect directly opposite to this was observed in kidneys ofcontrol mice (41). Thus, the evidence for chymase-dependent accumulation of Ang II in aged 330 hearts not only offers an explanation for the increase in Ang II paradoxically associated with 331 reductions in its precursor (Ang I) and ACE, but it additionally indicates a pathological 332 involvement of chymase in age-specific Ang II-generation via a distinctly different pathway 333 from that of the canonical ACE-dependent pathway. 334 335 Age-dependent compromise of the ACE2/Ang-1-7/MasR axis 336 ACE2 acts on Ang II to produce Ang 1-7 that binds to MasR and evokes protective 337
properties to counterbalance ACE/AT1R-dependent detrimental activity (48). Since the 338 discovery of ACE2 over a decade ago (18), a balance between these two opposing pathways 339 (ACE vs. ACE2) has served as an important parameter in pathophysiological evaluation of RAS 340 actions (42). In this context, not only the Ang II/ACE/AT1R axis, but also the ACE2/Ang 1-341 7/MasR arm merits consideration as regulatory targets in governing the function of RAS (58). In 342 accordance with this concept, altered actions of both pathways have been linked to a variety of 343 cardiovascular pathologies, including age-related cardiac dysfunction. For instance, renal ACE2 344 gene expression was downregulated in multiple hypertensive models (12). Moreover, 345 heterozygous ACE2-deficient animals were susceptible to heart diseases (59), and homozygous 346 ACE2-knockout mice developed an age-dependent cardiomyopathy with an accumulation of 347 cardiac Ang II (12). On the other hand, myocardial infarction-induced heart failure and ischemic 348 cardiomyopathy were reported to be alleviated significantly in response to administration of Ang an age-specific chymase-dependent increase in Ang II that is reversed by exercise training. Our 376 findings show a phenotype of exercise-induced optimal regulation of the ACE2/Ang 1-7/MasR 377 axis that is identical to those reported previously. This phenotype is characterized by the 378 potentiation of ACE2 activity (Figure 3) , restoration of Ang 1-7 levels ( Figure 1c ) and increase 379 in expression of MasR (Figure 6c ), leading to a reduction in Ang II (Figure 1b) and suppression 380 of superoxide ( Figure 5) . Nonetheless, the novel finding presented in the present study is that 381 increased exercise, independent of aging, can enhance ACE activity (Figure 2 ) and decrease 382 chymase activity (Figure 4 ). As such, the exercise-induced normalization of ACE (increased) and 383 chymase (decreased) work in concert with the upregulation of ACE2 to shift the RAS pathway 384 away from Ang II production toward production of Ang 1-7. This shift is accomplished by 385 favoring ACE2-mediated degradation of Ang II to Ang 1-7, and Ang I to Ang 1-9, the latter of 386 which is subsequently converted by the corrected ACE activity to further increase Ang 1-7 387 content in the tissue. In addition, even in the absence of significant effects on AT1R (Figure 6a) , 388 exercise can still amplify Ang 1-7-mediated cardioprotective responses (Figure 7 ) through the 389 upregulation of downstream MasR expression (Figure 6c) . 390
Perspectives and Alternatives 392
The literature is replete with studies that highlight a residual risk of cardiovascular events 393 in patients who are treated with RAS inhibitors, a phenomenon that has been attributed to 394 insufficient inhibition of Ang II synthesis or incomplete blockade of intracellular-based actions 395 of Ang II (51). Pharmacological approaches that prevent Ang II synthesis, inhibit ACE activity, 396 and block the peptide binding to AT1R epitomize the foundation of current treatment and 397 prevention strategies against heart diseases. However, these therapies fail to effectively inhibitthe intracellular formation or activity of Ang II. Thus, the broader implication of the present 399 study, which shows an age-specific increase in chymase-dependent Ang II production, is that 400 ACE inhibitors alone may not be sufficient for preventing cardiac functional decline in aged 401 populations; they may require combinatorial treatment with both ACE and chymase inhibitors to 402 optimally protect the elderly heart from Ang II-induced deteriorations. On the other hand, while 403 this study indicates a correlation between cardiac chymase and age, it has not yet provided a 404 functional link between the chymase-dependent formation of Ang II and changes in cardiac 405 function, or explored possible mechanisms responsible for the exercise-dependent modulation of 406 functional changes via providing chymase inhibitors; these issues will be clarified in our future 407 studies. 
